Abstract 1050P
Background
Despite recent advances in the use of immunotherapy only a minority of cancers respond to immune checkpoint blockade (ICB). Current cytotoxic drug treatments for small cell lung cancer (SCLC) have been known to act by induction of DNA damage. These notable results can be explained by high number of genomic aberrations observed in SCLC combined with rapid cellular proliferation resulting in accumulation of DNA damage and genomic instability. SCLC cells are reliant on DNA damage repair pathways and transcription proficiency. Recent preclinical data have shown that the DDR influences multiple aspects of tumor immunogenicity. We propose the sensitizing of ICB resistant tumors through transcriptional stress by exposure to the RNA Pol II inhibitor lurbinectedin (LUR). 2SMALL is a two-part phase 1/2 study assessing the safety, tolerability and efficacy of LUR in combination with atezolizumab (ATZ) as second line treatment for ES-SCLC.
Methods
2SMALL phase I was an open-label, single arm, dose exploration trial. ES-SCLC patients received increasing doses of LUR plus a fixed dose of ATZ every 3 weeks following a standard 3+3 dose escalation design. Study endpoints included the definition of the safety profile and the recommended dose. Additional objectives included efficacy (ORR and PFS). A syngeneic immunocompetent mice model for SCLC (Rb-/-p53-/-) has been used to identify the efficacy of LUR in combination with an anti PD-L1 mAb. The role of LUR at inducing DNA sensing pathways was evaluated in several cell lines, PDX derived organoids and ex vivo.
Results
Objective responses were observed in 15 pts (ORR: 57.69%), including complete responses in 2 pts (7.69%), partial response in 13 pts (50%). 6 pts had stable disease (26.92%) and 3 pts progressive disease (11.54%). Disease control rate was 84.61 %, median PFS was 4.93 months (range 3.37 - 7.67 months). Type I IFN pathway, proinflammatory cytokines, chemokines and PD-L1 were upregulated by LUR in SCLC models.
Conclusions
Combination of LUR plus ATZ was well tolerated, with no unexpected toxicities. Preliminary anti-tumor activity is remarkable. Our results show effective tumor-activating IFN type 1, which increases immunity against tumors and provides the rationale to combine DDR inhibitors with ICBs.
Clinical trial identification
NCT04253145.
Editorial acknowledgement
Legal entity responsible for the study
Oncosur Foundation & Luis Paz-Ares.
Funding
Oncosur Foundation.
Disclosure
A.F. Navarro Mendivil: Financial Interests, Personal, Advisory Board: Boehringer Ingelheim, Oryzon Genomics, Amgen, Hengenix Biotech, MedSIR, BMS; Financial Interests, Personal, Invited Speaker: Roche, AstraZeneca, Pfizer, Takeda; Non-Financial Interests, Principal Investigator: BMS, PharmaMar, MSD, Amgen, Novartis, Debiopharm, Daiichi Sankyo, Roche, AstraZeneca. L. Paz-Ares: Financial Interests, Personal, Advisory Board, Speaker fees: Roche, MSD, BMS, AZ, Lilly, PharmaMar, BeiGene, Daichii, Medscape, PER; Financial Interests, Personal, Advisory Board: Merck Serono, Pfizer, Bayer, Amgen, Janssen, GSK, Novartis, Takeda, Sanofi, Mirati; Financial Interests, Personal, Other, Board member: Genomica, Altum sequencing; Financial Interests, Institutional, Coordinating PI: Daiichi Sankyo, AstraZeneca, Merck Sharp & Dohme corp, BMS, Janssen-cilag international NV, Novartis, Roche, Sanofi, Tesaro, Alkermes, Lilly, Takeda, Pfizer, PharmaMar; Financial Interests, Personal, Coordinating PI: Amgen; Financial Interests, Other, Member: AACR, ASCO, ESMO; Financial Interests, Other, Foundation Board Member: AECC; Financial Interests, Other, President.ASEICA (Spanish Association of Cancer Research): ASEICA; Financial Interests, Other, Foundation president: ONCOSUR; Financial Interests, Other, member: Small Lung Cancer Group. All other authors have declared no conflicts of interest.
Resources from the same session
1343P - Amivantimab as a salvage strategy post TKI (osimertinib/mobocertinib) in EGFRm NSCLC
Presenter: Bilal Krayim
Session: Poster session 19
1344P - A real-world (rw) observational study of long-term survival (LTS) and treatment patterns after first-line (1L) osimertinib in patients (pts) with epidermal growth factor receptor (EGFR) mutation-positive (m) advanced non-small cell lung cancer (NSCLC)
Presenter: Jorge Nieva
Session: Poster session 19
1345P - Preclinical activity of ORIC-114, a highly selective, brain penetrant, irreversible kinase inhibitor, against atypical mutations in EGFR
Presenter: Melissa Junttila
Session: Poster session 19
1346P - Efficacy and safety of high dose furmonertinib combined with intrathecal injection in EGFR-mutated advanced NSCLC patients with LM progressed on osimertinib
Presenter: Xiaoyan Li
Session: Poster session 19
1348P - Management of paresthesia in patients treated with lazertinib: Integrated analysis of LASER201 and LASER301 studies
Presenter: Yun-Gyoo Lee
Session: Poster session 19
1349P - Continuing osimertinib in combination with chemotherapy after osimertinib failure reduces CNS progression in patients with EGFR-mutated NSCLC and CNS metastases
Presenter: Molly Li
Session: Poster session 19
1350P - Survival benefits of local treatment (LT) for brain metastases (BMs) in patients (pts) with EGFR-mutant non-small cell lung cancer (EGFR-mt NSCLC) treated with osimertinib
Presenter: Takehiro Tozuka
Session: Poster session 19
1351P - Efficacy of early stereotactic body radiotherapy to the primary lung lesion in patients with NSCLC harboring sensitive EGFR mutations treated with first-line EGFR-TKIs
Presenter: Dan Tao
Session: Poster session 19
1352P - Plasma metabolic signatures uncover therapeutic response and prognosis of third-generation EGFR-TKI treatment in patients with NSCLC
Presenter: Ruyun Gao
Session: Poster session 19